Literature DB >> 8536361

Cell cycling in HIV infection: analysis of in vivo activated lymphocytes.

M Mahalingam1, A Pozniak, T J McManus, D Vergani, M Peakman.   

Abstract

Infection with HIV results in increased circulating levels of T lymphocytes expressing phenotypic markers of immune activation. In the present study, using three-colour immunofluorescence, we examined the cell cycle status of these activated cells. Activated (HLA-DR+, CD25+ and CD38+) CD4+ and CD8+ T lymphocytes in peripheral blood were analysed for DNA content in 15 HIV+ patients and 10 healthy age- and sex-matched control subjects. As expected, all HIV+ patients had elevated percentage levels of activated CD4+ HLA-DR+, CD4+ CD25+, CD8+ HLA-DR+, CD8+ CD25+ and CD8+ CD38+ T lymphocytes compared with control subjects (P < 0.001 for all). Percentage levels of CD4+ HLA-DR+ and CD8+ HLA-DR+T lymphocytes in the 'proliferative' (S-G2M) phase of the cell cycle were also higher in the HIV+ patients compared with controls (P < 0.001 for both). The percentage levels of proliferative CD4+ CD25+, CD8+ CD25+ and CD8+ CD38+ lymphocytes were, however, similar in HIV+ patients and controls, indicating that the proliferative fraction of cells in vivo was confined to the HLA-DR+ subset and absent from the CD25+ and CD38+ populations. Four HIV+ patients had grossly elevated levels of CD8+ lymphocytes which were CD38+ (> 95%) and confined to the pre-G0-G1 phase of the cell cycle, suggesting these may be cells committed to apoptosis. These observations indicate an increase in the proliferative capacity of HLA-DR+ T lymphocytes in HIV infection in vivo. The reduced DNA content in other populations (e.g. CD38+ CD8+ lymphocytes) of some patients with advanced HIV disease suggests that these cells are apoptotic. Thus our results define both proliferative and apoptotic processes as a spectrum of activation-related events in HIV infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8536361      PMCID: PMC1553359          DOI: 10.1111/j.1365-2249.1995.tb03841.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

Review 1.  The biologic roles of CD2, CD4, and CD8 in T-cell activation.

Authors:  B E Bierer; B P Sleckman; S E Ratnofsky; S J Burakoff
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

2.  Simultaneous cell cycle analysis and two-color surface immunofluorescence using 7-amino-actinomycin D and single laser excitation: applications to study of cell activation and the cell cycle of murine Ly-1 B cells.

Authors:  P S Rabinovitch; R M Torres; D Engel
Journal:  J Immunol       Date:  1986-04-15       Impact factor: 5.422

3.  Impairment in T-lymphocyte responses during early infection with the human immunodeficiency virus.

Authors:  J Bentin; C D Tsoukas; J A McCutchan; S A Spector; D D Richman; J H Vaughan
Journal:  J Clin Immunol       Date:  1989-03       Impact factor: 8.317

4.  Serum increases and lymphoid cell surface losses of IL-2 receptor CD25 in HIV infection: distinctive parameters of HIV-induced change.

Authors:  B Hofmann; P Nishanian; J L Fahey; I Esmail; A L Jackson; R Detels; W Cumberland
Journal:  Clin Immunol Immunopathol       Date:  1991-11

5.  Selective loss of T cell functions in different stages of HIV infection. Early loss of anti-CD3-induced T cell proliferation followed by decreased anti-CD3-induced cytotoxic T lymphocyte generation in AIDS-related complex and AIDS.

Authors:  R A Gruters; F G Terpstra; R De Jong; C J Van Noesel; R A Van Lier; F Miedema
Journal:  Eur J Immunol       Date:  1990-05       Impact factor: 5.532

Review 6.  Features of apoptotic cells measured by flow cytometry.

Authors:  Z Darzynkiewicz; S Bruno; G Del Bino; W Gorczyca; M A Hotz; P Lassota; F Traganos
Journal:  Cytometry       Date:  1992

7.  Immune changes in HIV-1 infection: significant correlations and differences in serum markers and lymphoid phenotypic antigens.

Authors:  H Z Bass; P Nishanian; W D Hardy; R T Mitsuyasu; E Esmail; W Cumberland; J L Fahey
Journal:  Clin Immunol Immunopathol       Date:  1992-07

8.  CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group.

Authors:  J V Giorgi; H N Ho; K Hirji; C C Chou; L E Hultin; S O'Rourke; L Park; J B Margolick; J Ferbas; J P Phair
Journal:  J Infect Dis       Date:  1994-10       Impact factor: 5.226

9.  Effect of mitogens on the cell cycle progression and the quantification of T-lymphocyte surface markers in acquired immune deficiency syndrome.

Authors:  F J Hornicek; G I Malinin; J T Thornthwaite; M E Whiteside; C L MacLeod; T I Malinin
Journal:  J Leukoc Biol       Date:  1987-08       Impact factor: 4.962

10.  Flow cytometry and biochemical analysis of DNA degradation characteristic of two types of cell death.

Authors:  V N Afanas'ev; B A Korol; P A Nelipovich; V A Pechatnikov; S R Umansky
Journal:  FEBS Lett       Date:  1986-01-06       Impact factor: 4.124

View more
  11 in total

1.  Expression of MHC class II in T cells is associated with increased HIV-1 expression.

Authors:  M Saifuddin; G T Spear; C Chang; K A Roebuck
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  A single measurement of CD38CD8 cells in HIV+, long-term surviving injecting drug users distinguishes those who will progress to AIDS from those who will remain stable.

Authors:  K S Froebel; G M Raab; C D'Alessandro; M P Armitage; K M MacKenzie; M Struthers; J M Whitelaw; S Yang
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

3.  The CD8+ HLA-DR+ T cells expanded in HIV-1 infection are qualitatively identical to those from healthy controls.

Authors:  Hiromi Imamichi; Richard A Lempicki; Joseph W Adelsberger; Rebecca B Hasley; Alice Rosenberg; Gregg Roby; Catherine A Rehm; Amy Nelson; Sonya Krishnan; Mark Pavlick; Christian J Woods; Michael W Baseler; H Clifford Lane
Journal:  Eur J Immunol       Date:  2012-08-06       Impact factor: 5.532

4.  Effect of cell cycle arrest on the activity of nucleoside analogues against human immunodeficiency virus type 1.

Authors:  Sebastien Wurtzer; Séverine Compain; Henri Benech; Allan J Hance; François Clavel
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  Abnormal intracellular IL-2 and interferon-gamma (IFN-gamma) production as HIV-1-assocated markers of immune dysfunction.

Authors:  M Westby; J B Marriott; M Guckian; S Cookson; P Hay; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

Review 6.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

7.  In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine.

Authors:  M Tanaka; R V Srinivas; T Ueno; M F Kavlick; F K Hui; A Fridland; J S Driscoll; H Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

8.  Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection.

Authors:  K Steiner; I Waase; T Rau; M Dietrich; B Fleischer; B M Bröker
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

9.  Nonradioactive techniques for measurement of in vitro T-cell proliferation: alternatives to the [(3)H]thymidine incorporation assay.

Authors:  T Messele; M T Roos; D Hamann; M Koot; A L Fontanet; F Miedema; P T Schellekens; T F Rinke de Wit
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

10.  Immune activation and viral replication after vaccination with an influenza A H1N1 2009 vaccine in HIV-infected children receiving antiretroviral therapy.

Authors:  Nattawat Onlamoon; Petai Unpol; Michittra Boonchan; Kasama Sukapirom; Orasri Wittawatmongkol; Kulkanya Chokephaibulkit; Palanee Ammaranond; Kovit Pattanapanyasat
Journal:  Dis Markers       Date:  2013-09-05       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.